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INTRODUCTION 
 
Conventional cancer treatments, such as inhibitors 
of S phase or mitosis, target all the proliferating cells 
and therefore cause many side effects. The new 
“targeted” chemotherapy drugs, such as imatinib, 
which attack tumor cells by one specific mechanism, 
are generally safer and have fewer side effects; but, 
have typically shown initial success followed by 
recurrence and resistance. Successful treatment of 
cancers generally requires the use of multiple 
chemotherapeutic agents, but physicians are limited by 
the limited number of mechanistically unique 
chemotherapy drugs available. Therefore, identification 
of new drugs that target distinct properties of cancers is 
critically needed. 
Defects in cancer cells that lead to uncontrolled 
proliferation usually include both deregulated 
oncogenic activation as well as inactivated tumor 
suppressors.  The deregulated oncogenic signaling 
components are well recognized to be potential targets 
for new cancer drugs since blocking the deregulated 
oncogenic signaling inhibits cell proliferation and 
induces cell death.  In contrast, loss of tumor 
suppressors in cancers is not easily exploited for 
developing cancer therapeutics due to the lack of 
approaches to restore the lost tumor suppressor 
function in all cancer cells.  An alternative approach to 
restoring the tumor suppressor function in cancer cells 
is to specifically kill cancer cells that have the 
inactivated tumor suppressor.  However, it is difficult 
to identify genes that will cause synthetic lethality 
(induction of cell death only when both the tumor 
suppressor and the gene are inactivated).   Our lab has 
developed a screen to identify genes that are synthetic 
lethal in combination with the tumor suppressor gene 
Retinoblastoma (Rb), using the model system 
Drosophila melonogaster [1]. 
 
INACTIVATION OF TSC2 AND RB LEADS TO 
SYNERGISTIC CELL DEATH INDUCTION 
 
Retinoblastoma or Rb is a tumor suppressor protein 
that was first identified in children that exhibited 
tumors of the retina.  Rb functions primarily by binding 
to the E2F transcription factors, which are regulated by 
the cyclin dependent kinases.  E2F proteins regulate the 
transcription of many types of genes including genes 
involved in cell cycle, DNA repair, differentiation, and 
metabolism (reviewed in [2, 3]).  The Rb-E2F pathway 
also plays a role in apoptosis by regulating the 
transcription of cell death targets such that Rb mutant 
cells are sensitized for cell death (Fig.1) [4]. Since Rb 
and other components of the Rb signaling pathway are 
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ABSTRACT: 
Retinoblastoma (Rb), a tumor suppressor gene, is inactivated in many types of 
cancer. However little is known about how the loss of Rb function can be targeted in 
cancer therapies. We have identified that inactivation of TSC2 in Rb mutant cancer 
cells will induce a synergistic cell death.   The synergistic cell death is due to an 
increase in cellular stress including, metabolic, ER, and oxidative stress.  Therefore, 
inactivation of TSC2 and chemothereputics that result in induction of cellular stress 
may be a novel and effective way to treat cancers containing inactivated Rb.     
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often found to be inactivated in a variety of cancers, 
loss of Rb is a good candidate for targeted drug 
therapies.  
Using the screen in Drosophila to identify Rb 
synthetic lethal genes, we reported the identification of 
a mutation in the TSC2 homologue (gigas) that caused 
a synergistic cell death induction with loss of the  Rb 
homogogue in Drosophila [1].   
Mutations in TSC2 (or TSC1) result in a disease 
called Tuberous sclerosis that causes benign tumors in 
several different organs as well as neural defects 
(reviewed in [5-7]).  TSC1 and TSC2 are part of the 
TOR signaling pathway which is responsible for 
sensing nutrient availability and growth factors and 
inducing the appropriate metabolic changes for the cell.  
The TSC complex is a GAP (GTPase activating 
protein), which promotes the conversion of GTP-bound 
Rheb to the inactive GDP-bound Rheb. Inactivation of 
TSC2 leads to deregulated TORC1 activity, which 
promotes protein synthesis, induces increased oxidative 
phosphorylation and cellular stress, and inhibits 
autophagy (Fig. 1) [6].   
To test whether inactivation of TSC2 can be used to 
specifically kill Rb mutant cancers, we used lentivirus 
to express short hairpin RNA specific to TSC2 
(shTSC2) in Rb mutant and Rb wild type cancer cells.  
Our results showed that shTSC2 increased cell death 
under a variety of stress conditions and  inhibited the 
growth of Rb mutant cells in soft agar and in mouse 
xenografts [1].  These results suggested that TSC2 is a 
good protein to inactivate in order to specifically kill 
Rb mutant cancers.   
 
MECHANISMS OF CELL DEATH IN TSC2 
INACTIVATED-RB MUTANT CANCER CELLS 
 
Inactivation of TSC2 resulted in a decreased level 
of Akt signaling.  PI3K/Akt is a major component of 
survival signaling that modulates E2F-mediated cell 
death [8], suggesting that decreased PI3K/Akt survival 
signaling may contribute to shTSC2-induced cell death. 
In support of this idea, microarray analysis revealed 
that shTSC2 significantly reduced expression of 
components of the insulin-like growth 
factor/EGF/PI3K survival signaling pathways and 
reduced the level of survival factors such as Bcl-XL 
[1]. Additionally, expression of Bcl-XL significantly 
decreased shTSC2 induced cell death; suggesting that 
the reduced survival signaling contributes to shTSC2-
induces cell death in Rb mutant. 
However, decreasing the level of survival signaling 
is not the only and perhaps not the primary mechanism 
by which shTSC2 induces cell death as overexpression 
of activated Akt failed to inhibit cell death in Rb, TSC2 
inactivated cells [1]. While Akt can protect cells from 
undergoing cell death induced by a variety of cell death 
signals, AKT does not protect cells from cell death 
induced by ROS [9]. Indeed inactivation of both TSC2 
and Rb synergistically induce a high level of cellular 
stress, including oxidative stress and ER stress, which 
are critical for synergistic cell death induction. In both 
flies and human cancer cells, synergistic cell death is 
E2F-dependent and mediated by enhanced protein 
synthesis due to increased TORC1 activity. Decreasing 
the level of protein synthesis, either by inactivation of 
S6K in flies or by treatment of cancer cells with G418, 
significantly inhibited synergistic cell death induction 
[1].  These results suggest that enhanced protein 
synthesis is a key contributor of shTSC2-induced cell 
death.   
Enhanced protein synthesis can lead to low ATP 
levels and increased metabolic stress, which in turn can 
induce increased oxidative phosphorylation in the 
mitochondria and decreased lipid synthesis.  Increased 
oxidative phosphorylation causes an increased level of 
reactive oxygen species (ROS). To show that shTSC2 
induces an oxidative state to the Rb mutant cancer 
cells, (Du145), we used a redox sensitive form of 
EGFP (roGFP), which loses florescence in the 
Fig. 1: A model of inactivation of Rb and 
TSC2 results in synergistic cell death.  
Inactivation of TSC2 results in deregulation of 
TORC1 signaling, which in turn leads to increased 
cellular stress (including metabolic stress, ROS, 
and ER stress) and decreased Akt survival 
signaling. Inactivation of Rb leads to activation of 
E2F transcription factors which in turn results in 
the upregulation of genes that promote cell death 
as well as a failure to upregulate genes (such as 
SOD2) that protect cells from increased cellular 
stress. Our model suggests that inactivation of Rb 
and TSC2 leads to an accumulation of cellular 
stress as well as cell death signals, resulting in 
synergistic cell death induction.  
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oxidative state. As shown in Fig. 2, while neither 
H2O2 nor antioxidant NAC significantly affect EGFP 
fluorescence signal (Fig. 2A-D), H2O2 significantly 
decreased fluorescence signal from roGFP1 (Fig. 2G).  
Interestingly, shTSC2 significantly decreased the 
roGFP1 but not the EGFP signal (Fig. 2B and F), 
supporting the idea that inactivation of TSC2 induces 
an oxidative state in the cells.  
Cancer cells often exhibit increased de novo lipid 
synthesis. In fact, inhibition of de novo lipid or 
cholesterol synthesis can suppress tumor cell growth 
and induce cell death [10-12]. Interestingly, microarray 
analysis revealed that shTSC2 led to significant 
inhibition of the key enzymes in lipid synthesis, but not 
in the adapted cells that developed resistance to 
shTSC2-induced cell death. Furthermore, an increased 
level of ER stress is observed in TSC2 knockdown Rb 
mutant cells but not in the adapted cells [1].  These 
results suggested that an inhibition of lipid synthesis in 
conjunction with increased protein synthesis induces an 
increased level of ER stress, which may also contribute 
to synergistic cell death. 
While TSC2 inactivation plays a key role in 
inducing cellular stress, it appears that Rb plays an 
important role in the cells ability to deal with increased 
cellular stress. SOD2, AMPKα2, and GRP78/BiP, 
which are important regulators of oxidative stress, 
metabolic stress, and ER stress, respectively; have been 
reported to be targets of the E2F transcription factors 
[8, 13, 14]. We showed that Rb regulates SOD2 
expression. In the absence of Rb, SOD2 expression 
failed to be upregulated by shTSC2 [1]. Therefore, Rb 
mutant cells accumulate high levels of ROS upon 
TSC2 knockdown and are more sensitive to shTSC2-
induced cell death. It will be interesting to test if 
AMPKα2 and GRP78/BiP are also regulated by Rb and 
contribute to Rb and TSC2 inactivation induced cell 
death. 
In flies we found that inhibiting the JNK signaling 
pathway, which is the key stress signaling pathway in 
flies, led to a decrease in cell death in the cells mutant 
for the homologs of Rb and TSC2 [1].  These results 
suggested that in both flies and mammalian cells the 
inhibition of TSC2 function can lead to increased stress 
signaling that in turn leads to an increase in cell death.   
In summary, we propose a model in which Rb 
mutant cells are (1) already sensitized to apoptosis as 
inactivation of Rb can lead to upregulation of E2F 
Fig. 2:  TSC2 knockdown in Rb mutant cancer cells induces an increase in ROS.  roGFP1 is a
redox-sensitive variant of EGFP which exhibits a decrease in florescence intensity in an oxidative state.  Du145
cells containing either EGFP or roGFP1 were treated as shown.  A-D) The fluorescence intensity of EGFP did
not vary with redox status.  E-H) The intensity of the florescent signal of roGFP decreased when cells were in an
oxidative state (H2O2, G) as compared to control (E) but remained the same when treated with NAC, an
inhibitor of ROS (H).  Knocking down TSC2 (shTSC2) resulted in an oxidative state in the cells (compare E and
F). For experimental details, see reference [1]. 
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mediated transcription of apoptotic factors and (2) 
sensitized to increased cellular stress due to defects in 
the regulation of proteins that modulate cellular stress 
such as SOD2 (Fig. 1).  Therefore, inactivation of 
TSC2 which results in increased cellular stress 
including oxidative, ER and metabolic stress can “tip 
the scale” toward induction of cell death.  
   
THERAPIES FOR RB MUTANT CANCERS 
 
Our model clearly illustrates the interconnectedness 
of metabolic regulation, cell stress, proliferation and 
apoptotic signaling pathways.  Cancer cells are known 
to have altered metabolism, exhibiting enhanced 
aerobic glycolysis and de novo lipid synthesis [3, 12, 
15]. Interestingly, some of the same proteins that 
regulate cell proliferation such as oncogenes, tumor 
suppressors and cell cycle checkpoint proteins also 
regulate metabolic processes in the cell [3, 16, 17]. The 
altered metabolism in cancer cells potentially offers 
new drug targets for the treatment of cancer and these 
types of new drug targets will likely be useful for 
simultaneously targeting multiple pathways to 
efficiently induce cell death and to prevent the 
development of resistance.  We observed that 
inactivation of Rb and TSC2 synergistically induce cell 
death due to cellular stress induced by altered 
metabolism, suggesting that agents that target the 
metabolic pathways may enhance TSC2 inactivation 
induced specific killing of the Rb mutant cancer cells 
by inducing increased cellular stress. 
Rb is inactivated in a large number of cancers, 
making Rb a potentially ideal candidate for finding 
treatments for these cancers.  Since shRNA will be 
difficult to use in cancer treatment, it is likely that 
small molecule inhibitors of TSC2 function will need 
to be developed for the treatment of Rb mutant cancers.   
In previous clinical trials it was found that 
inhibiting kinases in cancer treatment often leads to the 
development of resistant cancers.  It is possible that an 
inhibitor of TSC2 can be used in conjunction with 
drugs that target deregulated oncogenic activation to 
decrease the development of resistant cancers and 
achieve a better clinical outcome in Rb mutant cancers. 
We showed that inactivation of Rb and TSC2 induced 
cell death was mediated by increased cellular stress. 
Therefore, we suggest that agents that can modulate 
cellular stress, such as an activator of AMPK or 
inhibitors of lipid synthesis, could potentially enhance 
the killing of Rb mutant cancer cells by inhibiting 
TSC2.  In addition, since apoptosis induced by shTSC2 
in Rb mutant cells is affected by Bcl-Xl levels, 
inhibitor of Bcl-2 family of proteins, such as ABT-263 
or ABT-737 [18], [19], could also increase the efficacy 
of TSC2 inhibitor induced killing of Rb mutant 
cancers.   
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